These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8857746)

  • 1. Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM.
    Pizzolato G; Chierichetti F; Fabbri M; Cagnin A; Dam M; Ferlin G; Battistin L
    Neurology; 1996 Oct; 47(4):1065-8. PubMed ID: 8857746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography.
    Walker Z; Costa DC; Janssen AG; Walker RW; Livingstone G; Katona CL
    Eur J Nucl Med; 1997 Jun; 24(6):609-14. PubMed ID: 9169566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
    Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
    J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls.
    Eisensehr I; Linke R; Tatsch K; Kharraz B; Gildehaus JF; Wetter CT; Trenkwalder C; Schwarz J; Noachtar S
    Sleep; 2003 Aug; 26(5):507-12. PubMed ID: 12938802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability.
    Verhoeff NP; Kapucu O; Sokole-Busemann E; van Royen EA; Janssen AG
    J Nucl Med; 1993 Dec; 34(12):2076-84. PubMed ID: 8254390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism.
    Radau PE; Linke R; Slomka PJ; Tatsch K
    J Nucl Med; 2000 Feb; 41(2):220-7. PubMed ID: 10688103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [99mTc]TRODAT-1/[123I]IBZM SPECT studies of the dopaminergic system in Tourette syndrome.
    Hwang WJ; Yao WJ; Fu YK; Yang AS
    Psychiatry Res; 2008 Feb; 162(2):159-66. PubMed ID: 18248965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study.
    Boesch SM; Donnemiller E; Müller J; Seppi K; Weirich-Schwaiger H; Poewe W; Wenning GK
    Mov Disord; 2004 Nov; 19(11):1320-5. PubMed ID: 15390003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study.
    Hammesfahr S; Antke C; Mamlins E; Beu M; Wojtecki L; Ferrea S; Dinkelbach L; Moldovan AS; Schnitzler A; Müller HW; Südmeyer M
    Neurodegener Dis; 2016; 16(5-6):342-7. PubMed ID: 26978429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Initial experiences with 123-Iodine-IBZM neuroreceptor scintigraphy in extrapyramidal disorders].
    Pávics L; Dibó G; Ambrus E; Séra T; Vécsei L; Csernay L
    Orv Hetil; 2000 May; 141(20):1073-7. PubMed ID: 10851890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
    Brücke T; Podreka I; Angelberger P; Wenger S; Topitz A; Küfferle B; Müller C; Deecke L
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):220-8. PubMed ID: 1671782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
    Innis RB; Malison RT; al-Tikriti M; Hoffer PB; Sybirska EH; Seibyl JP; Zoghbi SS; Baldwin RM; Laruelle M; Smith EO
    Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study.
    Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Murray RM; Kerwin RW
    Br J Psychiatry; 1994 Jan; 164(1):16-26. PubMed ID: 8137105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.